Future Fridays

Be your own boss

During your PhD training, you all aim to publish articles and write your thesis. But a lot of the research you carry out may have commercial potential and can be used to start your own biotech Company!

Meet and listen to three professionals, who did it! How did they do it? And what did it take?

Brian Della Valle, Director in GLX Analytix, PostDoc
Fatima Al-Zahraa Al Atraktchi, Director PreDiagnose, adjunkt RUC
Lotte Strøbech, IVF Lab Director, Associate Professor
Jeroen Bakker, Senior Associate, Novo seeds

In this future Friday seminar we will touch upon interesting topics such as:

  • How can you get started?'
  • What steps you need to take to get there?
  • What are the main differences between a job as an entrepreneur and working in academia?
  • what makes your project an attractive investment idea?
  • Who can help you here?
  • Good pieces of advice to a fresh-out-of-University PhD's

After the sessions there will be opportunity to ask questions as well as time for networking.

Please sign up


Brian Della Valle obtained his PhD from University of Copenhagen, worked as a PostDoc also at University of Copenhagen and Århus University, Department of Biomedicine. Together with his long-time colleague Casper Hempel, he has identified a potentially novel biomarker class that may reveal brain diseases such as multiple sclerosis, Alzheimer’s and Parkinson’s Disease at a much earlier stage than current medical practice. Brian and Casper have together founded GLX ANALYTIX to bring the discovery to industrial application.

Fatima AlZahra'a Alatraktchi has an M.Sc. (Eng) from the Technical University of Denmark and a PhD in nanotechnology and molecular biology. She now works as an assistant professor at the Department of Science and Environment at Roskilde University and is the founder of the medico company PreDiagnose. This company is based on Fatima AlZahra’a Alatraktchi’s method for early detecting of bacterial infections. Moreover, Fatima is also an international TED speaker.

(see link TEDx Talk about using the communication of bacteria to predict pathogenic activity)

Dr. Lotte Strøbech obtained her DVM and PhD from the Royal Veterinary and Agricultural University in Copenhagen (now part of University of Copenhagen). She is CEO of EmbryoTrans Biotech ApS, which she co-founded in 2013, Scientific Advisor for IVF Bioscience, UK to whom she sold the IP rights in 2015. Inventor of a media range for bovine and equine in vitro embryo production distributed now through IVFBioscience, UK. She is also Associate Professor at University of Copenhagen, Board Member at Association of Embryo Technology in Europe (AETE) and the President of the Danish Society of Reproduction and Fetal Development.

Jeroen Bakker holds a PhD in Immunology from the University of Amsterdam and an MSc degree in Biomedical Sciences from the Leiden University with a specialization in entrepreneurship. Jeroen was chair of the Dutch Platform for Young Researchers in Nephrology and is currently part of REBBLS, a networking organization focusing on young biotech entrepreneurs in Denmark. Jeroen joined Novo Seeds in 2018 as a Senior Associate.

Prior to joining Novo, Jeroen worked as an Associate at M Ventures, the corporate venture capital arm of Merck, where
he focused on early-stage healthcare investments in Europe, United States and company creation for the Israel Incubator. He co-led the investment in Artsavit and served on the Boards of Vaximm and Artsavit as an observer. Before M Ventures, Jeroen was active as a consultant where he was instrumental in acquiring over EUR 10 million in non-dilutive funding for biotech and translational academic research. Jeroen started his career in biotech at Syntaxin (acquired by Ipsen) working on target identification.

What is Future Fridays?